Pachoula-Papasteriades C, Boki K, Varla-Leftherioti M, Kappos-Rigatou I, Fostiropoulos G, Economidou J
Immunology Department, Evangelismos Hospital, Athens, Greece.
Dis Markers. 1986 Jun;4(1-2):35-41.
Ninety-five rheumatoid arthritis patients treated with aurothiomalate and/or D-penicillamine have been studied for possible associations between HLA-A, -B, -DR antigens and various toxic reactions to the above drugs. HLA-DR3 and -DRw6 had a higher frequency in patients with toxic reactions (all types) than in patients without toxic reactions (28.5 per cent vs 13.0 per cent and 26.5 per cent vs 4.3 per cent, chi 2 = 2.6 and 7.2, respectively). HLA-B8 was found at a higher frequency in patients with proteinuria and other types of renal involvement (20.0 per cent vs 7.4 per cent in controls), whereas skin manifestations were mainly associated with the presence of HLA-DRw6. The lowest frequency of side-effects was seen in patients with HLA-DR1 and DR2 (10.2 per cent vs 28.3 per cent and 28.5 per cent vs 54.3 per cent, chi 2 = 3.9 and 5.5, respectively). In addition, seropositive patients possessing HLA-DR1, showed toxic reactions less frequently.
对95例接受金硫代苹果酸和/或青霉胺治疗的类风湿性关节炎患者进行了研究,以探讨HLA - A、- B、- DR抗原与上述药物各种毒性反应之间可能存在的关联。发生毒性反应(所有类型)的患者中HLA - DR3和 - DRw6的频率高于未发生毒性反应的患者(分别为28.5%对13.0%以及26.5%对4.3%,卡方检验分别为2.6和7.2)。蛋白尿及其他类型肾脏受累的患者中HLA - B8的频率较高(20.0%对对照组的7.4%),而皮肤表现主要与HLA - DRw6的存在相关。HLA - DR1和DR2的患者出现副作用的频率最低(分别为10.2%对28.3%以及28.5%对54.3%,卡方检验分别为3.9和5.5)。此外,携带HLA - DR1的血清阳性患者出现毒性反应的频率较低。